Easier and more accessible testing for SARS-CoV-2 (COVID-19)
Ubiquitome has partnered with the Yale School of Public Health to enhance public access to COVID-19 testing, with United States Food and Drug Administration (FDA) emergency use authorization (EUA) of the combination of SalivaDirect™ with Ubiquitome’s Liberty16 mobile real time-PCR.
In Yale testing the Liberty16 displayed performance similar to large, lab-bound instruments.
|Proteinase K||Primer/Probe||RT-qPCR kit||RT-qPCR instrument||LOD||Positive replicates||Mean Ct value (SD)|
|Thermo||IDT||NEB Luna (2x)||Agilent AriaMX||6 copies/μL||100% (20/20)||30.3 (0.4)|
|Thermo||Eurofins||NEB Luna (2x)||Liberty16||12 copies/μL||100% (20/20)||35.18 (0.7)|
|Thermo||IDT||NEB Luna (2x)||CFX384 Touch||6 copies/μL||100% (20/20)||36.25 (0.4)|
Testing people for SARS-CoV-2 (COVID-19) has just been made easier and more accessible with United States Food and Drug ...
"Costly instruments for real-time PCR analysis often stand in the way of equitable access for under resourced communities and countries and sustainability of testing systems"
Dr Anne Wyllie, Yale School of Public Health (on why they partnered with Ubiquitome)